RECRUITINGPhase 3INTERVENTIONAL
Epidemiology and Biomarker Study in Alzheimer's Disease
A Longitudinal, Prospective Epidemiology Study in Alzheimer's Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer's Disease (ANCHOR-AD)
About This Trial
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
Who May Be Eligible (Plain English)
Who May Qualify:
- The participant must self-report unimpaired cognition.
- The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.
Who Should NOT Join This Trial:
- Have seen a doctor about memory concerns.
- Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition.
- Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention.
- Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* The participant must self-report unimpaired cognition.
* The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.
Exclusion Criteria:
* Have seen a doctor about memory concerns.
* Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition.
* Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention.
* Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine.
Treatments Being Tested
OTHER
P-tau217 Test
A plasma test measuring phosphorylated tau at Position 217 (P-tau217).
Locations (3)
Care Access - Houston
Houston, Texas, United States
The University of Tokyo Hospital
Bunkyō City, Japan
Souseikai Sumida Hospital
Tokyo, Japan